1	[	[	O	(	O	5	NMOD
2	Experimental	Experimental	B-NP	JJ	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	clinical	clinical	I-NP	JJ	O	5	NMOD
5	studies	study	I-NP	NNS	O	0	ROOT
6	of	of	B-PP	IN	O	5	NMOD
7	flomoxef	flomoxef	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	field	field	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	obstetrics	obstetric	B-NP	NNS	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	gynecology	gynecology	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	5	P

1	Representative	Representative	B-NP	JJ	O	3	NMOD
2	Committee	Committee	I-NP	NNP	O	3	NMOD
3	Members	Members	I-NP	NNP	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	Research	Research	I-NP	NNP	O	7	NMOD
7	Team	Team	I-NP	NNP	O	4	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	Infections	Infection	B-NP	NNPS	O	8	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	Field	Field	I-NP	NNP	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	Obstetrics	Obstetrics	B-NP	NNP	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	Gynecology	Gynecology	I-NP	NNP	O	13	PMOD
17	]	]	O	)	O	16	NMOD
18	.	.	O	.	O	3	P

1	Flomoxef	Flomoxef	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	FMOX	FMOX	B-NP	NN	B-protein	4	DEP
4	)	)	O	)	O	1	NMOD
5	has	have	B-VP	VBZ	O	24	VMOD
6	a	a	B-NP	DT	O	9	NMOD
7	broad	broad	I-NP	JJ	O	9	NMOD
8	antibacterial	antibacterial	I-NP	JJ	O	9	NMOD
9	spectrum	spectrum	I-NP	NN	O	5	OBJ
10	against	against	B-PP	IN	O	9	NMOD
11	Gram-positive	Gram-positive	B-NP	JJ	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	Gram-negative	Gram-negative	I-NP	JJ	O	14	NMOD
14	bacteria	bacteria	I-NP	NNS	O	10	PMOD
15	;	;	O	:	O	24	P
16	especially	especially	B-ADVP	RB	O	20	NMOD
17	its	its	B-NP	PRP$	O	20	NMOD
18	potent	potent	I-NP	JJ	O	20	NMOD
19	antibacterial	antibacterial	I-NP	JJ	O	20	NMOD
20	activity	activity	I-NP	NN	O	24	SUB
21	against	against	B-PP	IN	O	20	NMOD
22	Staphylococcus	Staphylococcus	B-NP	FW	O	23	NMOD
23	aureus	aureus	I-NP	FW	O	21	PMOD
24	is	be	B-VP	VBZ	O	0	ROOT
25	a	a	B-NP	DT	O	27	NMOD
26	significant	significant	I-NP	JJ	O	27	NMOD
27	advantage	advantage	I-NP	NN	O	24	PRD
28	that	that	B-NP	WDT	O	27	NMOD
29	may	may	B-VP	MD	O	28	SBAR
30	not	not	I-VP	RB	O	29	VMOD
31	be	be	I-VP	VB	O	29	VC
32	found	find	I-VP	VBN	O	31	VC
33	with	with	B-PP	IN	O	32	VMOD
34	other	other	B-NP	JJ	O	36	NMOD
35	cephem	cephem	I-NP	NN	O	36	NMOD
36	compounds	compound	I-NP	NNS	O	33	PMOD
37	.	.	O	.	O	24	P

1	In	In	B-PP	IN	O	0	ROOT
2	our	our	B-NP	PRP$	O	3	NMOD
3	determination	determination	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	its	its	B-NP	PRP$	O	7	NMOD
6	antibacterial	antibacterial	I-NP	JJ	O	7	NMOD
7	potency	potency	I-NP	NN	O	4	PMOD
8	against	against	B-PP	IN	O	7	NMOD
9	various	various	B-NP	JJ	O	11	NMOD
10	clinical	clinical	I-NP	JJ	O	11	NMOD
11	isolates	isolate	I-NP	NNS	O	8	PMOD
12	obtained	obtain	B-VP	VBN	O	11	NMOD
13	from	from	B-PP	IN	O	12	VMOD
14	clinical	clinical	B-NP	JJ	O	15	NMOD
15	materials	material	I-NP	NNS	O	13	PMOD
16	(	(	O	(	O	11	NMOD
17	amniotic	amniotic	B-NP	JJ	O	18	NMOD
18	fluid	fluid	I-NP	NN	O	21	NMOD
19	,	,	O	,	O	21	P
20	intrauterine	intrauterine	B-NP	JJ	O	21	NMOD
21	secretions	secretion	I-NP	NNS	O	37	SUB
22	,	,	O	,	O	37	P
23	exudates	exudate	B-NP	NNS	O	37	VMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	28	NMOD
26	pelvic	pelvic	I-NP	JJ	O	28	NMOD
27	dead	dead	I-NP	JJ	O	28	NMOD
28	space	space	I-NP	NN	O	24	PMOD
29	)	)	O	)	O	23	NMOD
30	of	of	B-PP	IN	O	23	NMOD
31	patients	patient	B-NP	NNS	O	30	PMOD
32	with	with	B-PP	IN	O	31	NMOD
33	various	various	B-NP	JJ	O	34	NMOD
34	infections	infection	I-NP	NNS	O	32	PMOD
35	,	,	O	,	O	37	P
36	we	we	B-NP	PRP	O	37	SUB
37	obtained	obtain	B-VP	VBD	O	16	SBAR
38	results	result	B-NP	NNS	O	37	OBJ
39	representing	represent	B-VP	VBG	O	38	NMOD
40	specific	specific	B-NP	JJ	O	41	NMOD
41	features	feature	I-NP	NNS	O	39	OBJ
42	of	of	B-PP	IN	O	41	NMOD
43	this	this	B-NP	DT	O	44	NMOD
44	drug	drug	I-NP	NN	O	42	PMOD
45	.	.	O	.	O	1	P

1	From	From	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	results	result	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	7	P
5	the	the	B-NP	DT	O	6	NMOD
6	drug	drug	I-NP	NN	O	7	SUB
7	may	may	B-VP	MD	O	0	ROOT
8	be	be	I-VP	VB	O	7	VC
9	expected	expect	I-VP	VBN	O	8	VC
10	to	to	I-VP	TO	O	11	VMOD
11	produce	produce	I-VP	VB	O	9	VMOD
12	an	an	B-NP	DT	O	14	NMOD
13	excellent	excellent	I-NP	JJ	O	14	NMOD
14	effect	effect	I-NP	NN	O	11	OBJ
15	in	in	B-PP	IN	O	11	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	treatment	treatment	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	various	various	B-NP	JJ	O	20	NMOD
20	infections	infection	I-NP	NNS	O	18	PMOD
21	.	.	O	.	O	7	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	study	study	I-NP	NN	O	12	SUB
3	on	on	B-PP	IN	O	2	NMOD
4	drug	drug	B-NP	NN	O	5	NMOD
5	concentrations	concentration	I-NP	NNS	O	3	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	body	body	B-NP	NN	O	8	NMOD
8	fluids	fluid	I-NP	NNS	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	genital	genital	B-NP	JJ	O	11	NMOD
11	tissues	tissue	I-NP	NNS	O	6	PMOD
12	demonstrated	demonstrate	B-VP	VBD	O	39	VMOD
13	a	a	B-NP	DT	O	15	NMOD
14	good	good	I-NP	JJ	O	15	NMOD
15	transfer	transfer	I-NP	NN	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	this	this	B-NP	DT	O	18	NMOD
18	drug	drug	I-NP	NN	O	16	PMOD
19	into	into	B-PP	IN	O	15	NMOD
20	various	various	B-NP	JJ	O	21	NMOD
21	tissues	tissue	I-NP	NNS	O	19	PMOD
22	;	;	O	:	O	39	P
23	in	in	B-PP	IN	O	39	VMOD
24	every	every	B-NP	DT	O	25	NMOD
25	tissue	tissue	I-NP	NN	O	23	PMOD
26	examined	examine	B-VP	VBN	O	25	NMOD
27	,	,	O	,	O	39	P
28	the	the	B-NP	DT	O	29	NMOD
29	drug	drug	I-NP	NN	O	39	SUB
30	administered	administer	B-VP	VBN	O	29	NMOD
31	by	by	B-PP	IN	O	30	VMOD
32	the	the	B-NP	DT	O	34	NMOD
33	usual	usual	I-NP	JJ	O	34	NMOD
34	method	method	I-NP	NN	O	31	PMOD
35	in	in	B-PP	IN	O	34	NMOD
36	the	the	B-NP	DT	O	38	NMOD
37	usual	usual	I-NP	JJ	O	38	NMOD
38	dose	dose	I-NP	NN	O	35	PMOD
39	yielded	yield	B-VP	VBD	O	0	ROOT
40	a	a	B-NP	DT	O	41	NMOD
41	concentration	concentration	I-NP	NN	O	39	OBJ
42	exceeding	exceed	B-VP	VBG	O	41	NMOD
43	MIC	MIC	B-NP	NN	O	42	OBJ
44	for	for	B-PP	IN	O	43	NMOD
45	principal	principal	B-NP	JJ	O	46	NMOD
46	pathogens	pathogen	I-NP	NNS	O	44	PMOD
47	,	,	O	,	O	39	P
48	thus	thus	B-ADVP	RB	O	49	VMOD
49	promising	promise	B-VP	VBG	O	39	VMOD
50	a	a	B-NP	DT	O	53	NMOD
51	good	good	I-NP	JJ	O	53	NMOD
52	clinical	clinical	I-NP	JJ	O	53	NMOD
53	response	response	I-NP	NN	O	49	OBJ
54	.	.	O	.	O	39	P

1	Indeed	Indeed	B-ADVP	RB	O	17	VMOD
2	a	a	B-NP	DT	O	6	NMOD
3	high	high	I-NP	JJ	O	6	NMOD
4	clinical	clinical	I-NP	JJ	O	6	NMOD
5	efficacy	efficacy	I-NP	NN	O	6	NMOD
6	rate	rate	I-NP	NN	O	17	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	90.1	90.1	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	7	PMOD
10	(	(	O	(	O	16	DEP
11	good	good	B-ADJP	JJ	O	16	DEP
12	to	to	B-PP	TO	O	11	AMOD
13	very	very	B-NP	RB	O	14	AMOD
14	good	good	I-NP	JJ	O	15	NMOD
15	responses	response	I-NP	NNS	O	12	PMOD
16	)	)	O	)	O	6	NMOD
17	was	be	B-VP	VBD	O	0	ROOT
18	obtained	obtain	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	a	a	B-NP	DT	O	22	NMOD
21	clinical	clinical	I-NP	JJ	O	22	NMOD
22	trial	trial	I-NP	NN	O	19	PMOD
23	involving	involve	B-VP	VBG	O	22	NMOD
24	222	222	B-NP	CD	O	25	NMOD
25	cases	case	I-NP	NNS	O	23	OBJ
26	.	.	O	.	O	17	P

1	Administration	Administration	B-NP	NN	O	10	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	drug	drug	I-NP	NN	O	2	PMOD
5	in	in	B-PP	IN	O	1	NMOD
6	2	2	B-NP	CD	O	8	NMOD
7	g	g	I-NP	NN	O	8	NMOD
8	quantity	quantity	I-NP	NN	O	5	PMOD
9	daily	daily	B-ADVP	RB	O	10	VMOD
10	produced	produce	B-VP	VBD	O	0	ROOT
11	a	a	B-NP	DT	O	14	NMOD
12	high	high	I-NP	JJ	O	14	NMOD
13	response	response	I-NP	NN	O	14	NMOD
14	rate	rate	I-NP	NN	O	10	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	92.8	92.8	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	10	P

1	It	It	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	especially	especially	B-ADJP	RB	O	4	AMOD
4	noteworthy	noteworthy	I-ADJP	JJ	O	2	PRD
5	that	that	B-SBAR	IN	O	2	VMOD
6	a	a	B-NP	DT	O	8	NMOD
7	good	good	I-NP	JJ	O	8	NMOD
8	response	response	I-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	5	SBAR
10	obtained	obtain	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	30	30	B-NP	CD	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	32	32	B-NP	CD	O	15	NMOD
15	cases	case	I-NP	NNS	O	13	PMOD
16	(	(	O	(	O	19	DEP
17	93.8	93.8	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	19	DEP
19	)	)	O	)	O	12	NMOD
20	in	in	B-PP	IN	O	12	NMOD
21	which	which	B-NP	WDT	O	20	PMOD
22	other	other	B-NP	JJ	O	24	NMOD
23	cephem	cephem	I-NP	NN	O	24	NMOD
24	compounds	compound	I-NP	NNS	O	25	SUB
25	had	have	B-VP	VBD	O	20	SBAR
26	failed	fail	I-VP	VBN	O	25	VC
27	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	0	ROOT
2	evaluation	evaluation	B-NP	NN	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	bacteriological	bacteriological	I-NP	JJ	O	6	NMOD
6	effect	effect	I-NP	NN	O	12	SUB
7	,	,	O	,	O	6	P
8	furthermore	furthermore	B-ADVP	RB	O	12	VMOD
9	,	,	O	,	O	12	P
10	the	the	B-NP	DT	O	11	NMOD
11	drug	drug	I-NP	NN	O	12	SUB
12	showed	show	B-VP	VBD	O	3	SBAR
13	an	an	B-NP	DT	O	15	NMOD
14	excellent	excellent	I-NP	JJ	O	15	NMOD
15	rate	rate	I-NP	NN	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	bacterial	bacterial	B-NP	JJ	O	18	NMOD
18	elimination	elimination	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	6	VMOD
2	conclusion	conclusion	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	6	P
4	this	this	B-NP	DT	O	5	NMOD
5	drug	drug	I-NP	NN	O	6	SUB
6	is	be	B-VP	VBZ	O	0	ROOT
7	expected	expect	I-VP	VBN	O	6	VC
8	to	to	I-VP	TO	O	9	VMOD
9	be	be	I-VP	VB	O	7	VMOD
10	greatly	greatly	B-ADJP	RB	O	11	AMOD
11	useful	useful	I-ADJP	JJ	O	9	PRD
12	in	in	B-PP	IN	O	11	AMOD
13	the	the	B-NP	DT	O	14	NMOD
14	light	light	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	its	its	B-NP	PRP$	O	18	NMOD
17	good	good	I-NP	JJ	O	18	NMOD
18	transfer	transfer	I-NP	NN	O	15	PMOD
19	into	into	B-PP	IN	O	18	NMOD
20	genital	genital	B-NP	JJ	O	21	NMOD
21	tissues	tissue	I-NP	NNS	O	19	PMOD
22	and	and	O	CC	O	6	VMOD
23	its	its	B-NP	PRP$	O	26	NMOD
24	strong	strong	I-NP	JJ	O	26	NMOD
25	antibacterial	antibacterial	I-NP	JJ	O	26	NMOD
26	activities	activity	I-NP	NNS	O	34	NMOD
27	against	against	B-PP	IN	O	26	NMOD
28	Gram-positive	Gram-positive	B-NP	JJ	B-protein	29	NMOD
29	cocci	coccus	I-NP	NNS	I-protein	27	PMOD
30	,	,	O	,	O	34	P
31	Gram-negative	Gram-negative	B-NP	JJ	O	32	NMOD
32	bacteria	bacteria	I-NP	NNS	O	34	NMOD
33	and	and	I-NP	CC	O	34	NMOD
34	anaerobes	anaerobe	I-NP	NNS	O	22	PMOD
35	as	as	B-CONJP	RB	O	34	NMOD
36	well	well	I-CONJP	RB	O	35	DEP
37	as	as	I-CONJP	IN	O	35	DEP
38	against	against	B-PP	IN	O	35	PMOD
39	multiple	multiple	B-NP	JJ	O	41	NMOD
40	bacterial	bacterial	I-NP	JJ	O	41	NMOD
41	infections	infection	I-NP	NNS	O	38	PMOD
42	predominating	predominate	B-VP	VBG	O	41	NMOD
43	among	among	B-PP	IN	O	42	VMOD
44	women	woman	B-NP	NNS	O	43	PMOD
45	with	with	B-PP	IN	O	44	NMOD
46	genital	genital	B-NP	JJ	O	47	NMOD
47	infections	infection	I-NP	NNS	O	45	PMOD
48	.	.	O	.	O	6	P

